Global Morpho Pharma

What Global Morpho Pharma does

Global Morpho Pharma is a French nuclear medicine startup founded in 2018 by five co-founders with combined experience exceeding 100 years. The company operates as a turnkey technology and service provider for the production and distribution of medical radioisotopes, specifically non-carrier-added (nca) Lutetium-177, Actinium-225, and Terbium-161, addressing supply-chain bottlenecks for targeted cancer radiotherapy. Its core proprietary platform, KaLupso, is described as the first fully automated and compact radiochemistry system for in-house GMP-grade production of nca Lu-177. KaLupso consists of three components: a dissolution unit that crushes quartz targets and dissolves irradiated Yb-176 powder, a chromatography unit that purifies Lu-177 with real-time online gamma-detection and drip-free column docking, and proprietary user-friendly software that automates parameter setting, monitoring, and recording with minimal operator hands-on time.

The business model is dual-pronged. Global Morpho Pharma sells and licenses KaLupso equipment for in-house production by radiopharmaceutical companies and nuclear medicine facilities, and also distributes finished radioisotopes through a global partner network covering Europe (NRG PALLAS in the Netherlands, SCK-CEN in Belgium), North America, and South America (Spectron RX). Revenue streams comprise one-time equipment/licensing sales, professional services and consumables (target material supply, irradiation coordination, installation, training, maintenance, recycling), and radioisotope distribution on a quote-based B2B pricing model. Strategic ownership includes a Framatome minority stake acquired in July 2022. The company is privately held as a French SAS with share capital of €247,757.01, has 1-10 employees, and targets commercial-scale delivery of Lu-177 chloride through its NRG PALLAS deployment from early 2027.

Name

Global Morpho Pharma

Legal name

Global Morpho Pharma SAS

Website

https://morphopharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Global Morpho Pharma is a French nuclear medicine startup founded in 2018 that provides turnkey technology and services for producing and distributing medical radioisotopes, notably nca Lutetium-177, via its proprietary KaLupso automated radiochemistry platform for radiopharmaceutical companies and nuclear medicine facilities.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing & Supply

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Irradiation Apparatus Manufacturing (334517), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

Keywords

• Medical radioisotope production
• Radiopharmaceutical manufacturing
• Automated radiochemistry equipment
• Nuclear medicine supply chain
• Targeted radionuclide therapy

Headquarters

HQ city

La Chapelle-sur-erdre

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. Radioisotope Sales: Sale of GMP-grade medical radioisotopes including nca Lu-177, Actinium-225, and Terbium-161 to radiopharmaceutical companies and nuclear medicine facilities worldwide.
2. KaLupso Equipment Sales and Licensing: Sale and licensing of KaLupso automated radiochemistry equipment for in-house production of medical radioisotopes. The equipment includes dissolution unit, chromatography unit, and proprietary software.
3. Technology and Services: Comprehensive services covering target material supply, target manufacturing, irradiation coordination, installation and training, maintenance, consumables, and target material recycling. Full lifecycle support for reactor-made medical isotope production.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Global Morpho Pharma sells and licenses the proprietary KaLupso automated radiochemistry platform, a turnkey system combining a dissolution unit, a chromatography unit, and proprietary software that enables radiopharmaceutical companies and nuclear medicine facilities to produce GMP-grade non-carrier-added Lutetium-177 in-house. The company complements this hardware with the distribution of GMP-grade medical radioisotopes (nca Lu-177, Actinium-225, Terbium-161) sourced through its global partner network, plus full lifecycle services spanning target material supply, irradiation coordination, installation, training, maintenance, consumables, and target recycling.

Product overview

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes, offering a platform-based approach centered on its proprietary KaLupso automated production system. The core KaLupso product consists of three integrated components—a dissolution unit, chromatography unit, and proprietary software—that together enable in-house production of pharmaceutical-grade non-carrier-added (nca) Lutetium-177. The company complements its equipment platform with comprehensive services spanning target material supply, manufacturing, irradiation coordination, processing (installation, training, maintenance), and target recycling. Global Morpho Pharma also distributes the radioisotopes themselves—nca Lu-177, Actinium-225, and Terbium-161—sourced through its global partner network. Partners can either purchase KaLupso equipment for in-house production or source finished radioisotopes directly from the company's distribution network.

Differentiator

Problem solved

Functional benefit

Brands

• KaLupso: Automated radiochemistry platform for nca Lu-177 production, consisting of a dissolution unit, chromatography unit, and proprietary user-friendly software.

Products and services

• KaLupso automated radiochemistry platform

Quantifiable outcome

• Over 100,000 patients worldwide could benefit annually from Lu-177-based therapies
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• NRG PALLAScoreStrategic or Co-development Partner · 31 March 2026Strategic partnership to implement sustainable and independent supply chain for n.c.a. Lutetium-177 chloride in Petten, Netherlands. NRG PALLAS deploys KaLupso technology within their GMP isotope production facility. The partnership creates a reliable, independent, and scalable source of supply for the radiopharmaceutical industry with initial commercial delivery targeted for early 2027. The collaboration offers integrated infrastructure with dedicated reactor and processing facility, optimized yield through co-location minimizing isotope decay, and fully automated GMP-compliant production.
• SCK-CENsecondaryChannel Partner/ Reseller/ Distributor · 9 September 2019Partnership with SCK-CEN (Belgian Nuclear Research Centre) as part of Global Morpho Pharma's global distribution network for medical radionuclides for targeted therapy. SCK-CEN joins the network alongside Spectron RX and the company's expert team.
• Spectron RXcoreChannel Partner/ Reseller/ Distributor · 22 June 2019Strategic partnership for North and South America distribution. Spectron RX provides therapeutic and diagnostic isotopes for clinical and research use and provides Contract Manufacturing Services. Together they are building a worldwide network covering the entire supply chain from original target to pharmaceutical grade radionuclide for human use.
• Lemer PaxcoreTechnology or IntegrationEquipment design and manufacturing partner. Lemer Pax, founded in 1970, is a historic leader in French nuclear medicine sector and world leader in radioprotection innovation with over 70 patents in past four years. Pierre-Marie Lemer serves as Chairman and Co-founder of Global Morpho Pharma while managing Lemer Pax.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IBA (Ion Beam Applications): Operates a radiopharma solutions business that includes radioisotope production (PET and SPECT tracers) and radiopharmacy networks, overlapping directly with Global Morpho Pharma's radiopharma customer base.
• Curium: One of the largest global manufacturers of medical radioisotopes (including Lu-177, Mo-99/Tc-99m), competing head-on with Global Morpho Pharma in supplying radiopharmaceutical companies and hospitals.
• NorthStar Medical Radioisotopes: US-based medical radioisotope producer focused on non-uranium Mo-99/Tc-99m and emerging Lu-177 production, serving the same radiopharma supply security use case as Global Morpho Pharma.
• ITM Isotope Technologies Munich: Direct peer in medical radioisotope production with a strong focus on nca Lutetium-177 and Actinium-225 for radiotheranostics — the same primary product lines as Global Morpho Pharma.

Broad incumbents

• Lantheus Holdings: Radiopharmaceutical company with commercial and pipeline radiodiagnostic/radiotherapy products, sourcing radioisotopes from producers like Global Morpho Pharma and competing for the same therapeutic nuclear medicine customers.
• BWX Technologies (BWXT Medical): Diversified nuclear operator with a medical isotopes business producing Mo-99 and other isotopes; broader portfolio player competing in the same nuclear medicine supply ecosystem.
• Framatome: Framatome holds a minority stake in Global Morpho Pharma and operates related medical isotope capabilities through its CERCA division (research reactor fuel/targets) and Canadian reactor Lu-177 production.

Emerging players

• SHINE Technologies: Emerging US medical isotope producer using fusion-based neutron technology for Mo-99 and Lu-177; competes on supply security and decoupled production, a similar value proposition to KaLupso.
• Telix Pharmaceuticals: Radiopharmaceutical company that sources Lu-177 and is a direct downstream customer/competitor in the radiotheranostics value chain, creating both a buyer and adjacent player for Global Morpho Pharma.

Regional players

• Spectron RX: US-based channel partner/distributor of Global Morpho Pharma's isotopes in the Americas; also provides its own contract manufacturing services, making it both a partner and a partial peer in radiopharma distribution.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/global-morpho-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Morpho Pharma